REG - Diaceutics PLC - Related Party Transaction - Lease Extension

DiaceuticsAnnouncement

Yesterday 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260416:nRSP8030Aa&default-theme=true

RNS Number : 8030A  Diaceutics PLC  16 April 2026

Diaceutics PLC

 

Related Party Transaction - Lease Extension

New York, Belfast and London, 16 April 2026 - Diaceutics PLC (AIM: DXRX), a
leading technology and solutions provider to the pharma and biotech industry,
announces that it has agreed an extension to its existing property lease
agreement for its Belfast headquarters with O'Connor & McCann Limited (the
'Lessor'). This constitutes a related party transaction under AIM Rule 13. The
Lessor continues to be a related party of the Company by virtue of Peter
Keeling, Non-Executive Chair of Diaceutics, being the sole director of the
Lessor. Persons closely associated with Peter Keeling hold 13.3% of the
Lessor.

 

Diaceutics (the 'Company') entered into a lease with the Lessor in 2021 at an
annual rent of £195,000, which was disclosed at the time as a related party
transaction. The lease had a ten-year term (ending in August 2031) with a
break clause exercisable after five years at which time the rent would be
subject to open market rent review.

 

Following negotiations, Diaceutics has agreed with the Lessor to extend the
lease term by five years from August 2031 to August 2036, securing the
longer-term future of the Company's headquarters in Northern Ireland. With
effect from August 2026, the annual rent will increase to £235,000, with an
open market rent review in August 2031 and no provision to terminate the lease
early. All other material provisions of the lease, including the Company's
right to sub‑lease the premises, remain unchanged.

 

The directors of the Company (excluding Peter Keeling), having consulted with
the Company's Nominated Adviser, consider that the terms of the lease
extension are fair and reasonable insofar as the Company's shareholders are
concerned.

 

Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer           Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer           investorrelations@diaceutics.com

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7253 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGMDZVLGVZM



            Copyright 2019 Regulatory News Service, all rights reserved